Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trastuzumab deruxtecan + paclitaxel + trastuzumab + pertuzumab
- Development stage
- Phase 3
- Lead developer
- Daiichi Sankyo
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This is a **combination regimen** composed of four agents: **trastuzumab deruxtecan**, **paclitaxel**, **trastuzumab**, and **pertuzumab**. - **Trastuzumab deruxtecan** is an antibody-drug conjugate targeting HER2 (human epidermal growth factor receptor 2), delivering a cytotoxic topoisomerase I inhibitor payload specifically to HER2-expressing cells. - **Paclitaxel** is a taxane-class microtubule inhibitor used as chemotherapy. - **Trastuzumab** and **pertuzumab** are both monoclonal antibodies directed against different domains of HER2, together providing dual blockade and enhancing antitumor activity through inhibition of proliferation, induction of ADCC (antibody-dependent cellular cytotoxicity), and complement-mediated cytotoxic effects[4]. This combination represents an investigational or off-label use (distinct from standard-of-care combinations) and may be studied in clinical trials as an experimental regimen for **HER2-positive metastatic breast cancer**.
- Other names
- Enhertu + paclitaxel + trastuzumab + pertuzumabEnhertu followed by paclitaxel, trastuzumab, and pertuzumabEnhertu followed by THPT-DXd + paclitaxel + trastuzumab + pertuzumabT-DXd followed by THPT-DXd-THPtrastuzumab deruxtecan + paclitaxel + trastuzumab + pertuzumabtrastuzumab deruxtecan followed by paclitaxel, trastuzumab, and pertuzumab
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on trastuzumab deruxtecan + paclitaxel + trastuzumab + pertuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trastuzumab deruxtecan + paclitaxel + trastuzumab + pertuzumab.